am 580 has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, L | 1 |
| DeMarco, SS | 1 |
| Peaks, MS | 1 |
| Maiorana-Boutilier, AL | 1 |
| Chen, J | 1 |
| Crouch, MJ | 1 |
| Shewchuk, BM | 1 |
| Shaikh, SR | 1 |
| Phillips, CM | 1 |
| Bridges, LC | 1 |
1 other study available for am 580 and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
RARĪ±/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Benzoates; Bexarotene; Cell Adhesion; Cel | 2017 |